Imagine if you could...

ADC connected to a therapeutic
Antibody with functional cytokines attached
Cell attached to a protein

CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by our technology, which can modify and combine proteins with complete freedom.

We have developed the CysTyr® platform utilizing the novel Catenase® enzyme, engineered to activate tyrosine residues with cysteine residues to form our proprietary C-Y Bond®.

Our platform redefines what therapeutics are possible, by removing longstanding limitations on the size, number, and type of molecules that can be attached to a single protein.

Imagine if you could...

ADC connected to a therapeutic
Antibody with functional cytokines attached
Cell attached to a protein

Significant barriers to production due to low yields and high cost to synthesize strained cyclooctyne reagents

Difficult; can’t make protein-protein bonds

Not stable

Selective

Low yields

Unstable reagents

Highly stable

Not selective to specific lysine

Requires organic solvents